| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (NCT03435796) | Celgene | 2018-07-19 |
| A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (NCT03573310) | Janssen Research & Development, LLC | 2018-07-13 |
| Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) (NCT03564691) | Merck Sharp & Dohme LLC | 2018-07-11 |
| Radiomics Multifactorial Biomarker for Pulmonary Nodules (NCT03872362) | Maastricht University | 2018-07-11 |
| A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours (NCT03468426) | Boehringer Ingelheim | 2018-07-05 |
| A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer (NCT03535727) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-06-21 |
| This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) (NCT03449381) | Boehringer Ingelheim | 2018-06-20 |
| Chest Imaging of Lung Nodule(s) Under High-frequency Non-invasive Ventilation (HF-NIV) (NCT03553368) | University of Lausanne Hospitals | 2018-06-14 |
| Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers (NCT03077477) | Aminex Therapeutics, Inc. | 2018-06-12 |
| A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile (NCT03416335) | Sumitomo Pharma America, Inc. | 2018-06-01 |
| Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis (NCT02606994) | Oral Defense, LLC | 2018-05-29 |
| Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors (NCT03510104) | Meryx, Inc. | 2018-05-22 |
| A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile (NCT03416816) | Sumitomo Pharma America, Inc. | 2018-05-15 |
| Extended Access of Momelotinib in Adults With Myelofibrosis (NCT03441113) | GlaxoSmithKline | 2018-05-03 |
| Facilitate the Return to Work of Cancer Survivors (NCT03666936) | Azienda USL Reggio Emilia - IRCCS | 2018-05-01 |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study (NCT03391778) | USWM CT, LLC | 2018-04-09 |
| Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors (NCT03447314) | GlaxoSmithKline | 2018-03-26 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (NCT03434262) | St. Jude Children's Research Hospital | 2018-03-05 |
| Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor (NCT03521037) | pharmaand GmbH | 2018-02-27 |
| This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (NCT03433898) | Boehringer Ingelheim | 2018-02-23 |
| Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (NCT03359850) | Tesaro, Inc. | 2018-02-20 |
| Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy (NCT03333655) | Hoffmann-La Roche | 2018-02-16 |
| Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer (NCT03384316) | National Cancer Institute (NCI) | 2018-01-31 |
| Livestrong Cancer Institutes' Patient Reported Outcomes Study (NCT04627077) | University of Texas at Austin | 2018-01-22 |
| Evaluation of the Efficiency of the IsereADOM Home-care Service Package in the Prevention of Unplanned Hospitalizations of Patients With Cancer (NCT03330730) | Centre Leon Berard | 2018-01-11 |
| EfiKroniK Research Program: Physical Exercise for People With Chronic Pathologies (NCT03810755) | Basque Health Service | 2018-01-10 |
| Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity (NCT03553654) | University of California, San Diego | 2018-01-09 |
| Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes (NCT07513259) | Chung Shan Medical University | 2018-01-01 |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT03373019) | Fudan University | 2017-12-21 |
| Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function (NCT03351140) | GlaxoSmithKline | 2017-12-20 |
| A Multi-center, Prospective, Single-blind, Controlled Trial Comparing Diagnostic Value of Different EUS-FNA Techniques (NCT03674710) | Shanghai Zhongshan Hospital | 2017-12-18 |
| Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule (NCT03329001) | Tesaro, Inc. | 2017-12-04 |
| The "Hand-in-Hand Study": Improvement of Quality of Life in Palliative Cancer Patients Through Collaborative Advance Care Planning (NCT03387436) | PD. Dr. med. Carola Seifart | 2017-12-04 |
| Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer (NCT03336567) | GlaxoSmithKline | 2017-12-04 |
| A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors (NCT03343054) | Pfizer | 2017-11-30 |
| Topical Curcumin for Precancer Cervical Lesions (NCT02944578) | Lisa Flowers | 2017-11-20 |
| Avelumab in Refractory Testicular Germ Cell Cancer. (NCT03403777) | National Cancer Institute, Slovakia | 2017-11-15 |
| Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery (NCT03072186) | Ohio State University | 2017-11-06 |
| MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric? (NCT03299855) | Centre Francois Baclesse | 2017-10-13 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy (NCT03270176) | Debiopharm International SA | 2017-10-10 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants (NCT03308942) | Tesaro, Inc. | 2017-09-29 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| Sample Collection and Tracking for the Developmental Therapeutics Clinic (NCT03269578) | National Cancer Institute (NCI) | 2017-08-28 |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (NCT02943733) | University of Wisconsin, Madison | 2017-08-22 |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma (NCT03168438) | GlaxoSmithKline | 2017-08-18 |
| ERANet-LAC CODE: International Care Of the Dying Evaluation (NCT03566732) | University of Bergen | 2017-08-15 |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors (NCT02723864) | National Cancer Institute (NCI) | 2017-08-09 |
| OMO-1 in Solid Malignancies (NCT03138083) | Octimet Oncology N.V. | 2017-08-08 |
| Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (NCT03250832) | Tesaro, Inc. | 2017-08-08 |
| First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors (NCT03084926) | Molecular Partners AG | 2017-08-08 |
| CAREgiver Study for Patients Undergoing HSCT (NCT03210727) | Dartmouth-Hitchcock Medical Center | 2017-07-25 |
| Community-Led Action Research in Oncology: Improving Symptom Management (NCT03208816) | Dartmouth-Hitchcock Medical Center | 2017-07-24 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (NCT03220347) | Celgene | 2017-07-24 |
| A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer (NCT03194893) | Hoffmann-La Roche | 2017-07-05 |
| Oxidoreductive Balance and Lysosomal Activity in Cancer Patients. (NCT03470857) | Nicolaus Copernicus University | 2017-06-19 |
| This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (NCT03156114) | Boehringer Ingelheim | 2017-06-13 |
| A Study of AK-01 (LY3295668) in Solid Tumors (NCT03092934) | Eli Lilly and Company | 2017-05-29 |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (NCT03102320) | Bayer | 2017-05-26 |
| This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (NCT03099174) | Boehringer Ingelheim | 2017-05-04 |
| Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer (NCT03096093) | Cancer Vaccines Limited | 2017-04-25 |
| International Lung Screen Trial (ILST) (NCT02871856) | The University of Queensland | 2017-04-05 |
| Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks (NCT03336489) | Fondation Ophtalmologique Adolphe de Rothschild | 2017-03-29 |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer (NCT03096340) | Intezyne Technologies, Inc. | 2017-03-23 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
| Endoscopic Resection Multicenter Registry (NCT03065257) | Weill Medical College of Cornell University | 2017-03-15 |
| The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types (NCT03085888) | GRAIL, Inc. | 2017-02-28 |
| Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients (NCT02944045) | Assistance Publique - Hôpitaux de Paris | 2017-02-15 |
| Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) (NCT02972034) | Merck Sharp & Dohme LLC | 2017-01-13 |
| A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects (NCT02798978) | GlaxoSmithKline | 2017-01-10 |
| Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics (NCT03027401) | National Cancer Institute (NCI) | 2017-01-10 |
| Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study (NCT02984163) | University of Alberta | 2017-01-09 |
| Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) (NCT02964013) | Merck Sharp & Dohme LLC | 2016-12-13 |
| Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma (NCT02992743) | GlaxoSmithKline | 2016-12-06 |
| Salivary Cytokines as Biomarker for Oral Health (NCT02807519) | University Hospital, Basel, Switzerland | 2016-12-01 |
| Biomarkers For Immune Checkpoint Inhibitors (NCT04204434) | Rhode Island Hospital | 2016-11-29 |
| A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours (NCT02952248) | Boehringer Ingelheim | 2016-11-21 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers (NCT02908906) | Janssen Research & Development, LLC | 2016-11-21 |
| Implementation of a Program Based on Adapted Physical Activity and Recommendations for Second Cancers Prevention for TYACs (NCT03336905) | Centre Leon Berard | 2016-11-09 |
| uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer (NCT02960724) | Rigshospitalet, Denmark | 2016-11-01 |
| Tumor Response in Hypofractionated Radiotherapy (NCT02854449) | Peking University First Hospital | 2016-11-01 |
| Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC (NCT03360630) | Capital Medical University | 2016-11-01 |
| Study of ASN003 in Subjects With Advanced Solid Tumors (NCT02961283) | Asana BioSciences | 2016-10-01 |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (NCT02909452) | Syndax Pharmaceuticals | 2016-09-20 |
| Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors (NCT02859857) | Bexion Pharmaceuticals, Inc. | 2016-09-01 |
| Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab (NCT02909348) | Royal Free Hospital NHS Foundation Trust | 2016-09-01 |
| Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors (NCT03190811) | Capital Medical University | 2016-09-01 |
| Profiling Neutrophil Counts in Patients on Chemotherapy (NCT02806557) | University of Leeds | 2016-09-01 |
| A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas (NCT02875223) | Celgene | 2016-08-31 |
| An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NCT02783300) | GlaxoSmithKline | 2016-08-30 |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (NCT02690545) | UNC Lineberger Comprehensive Cancer Center | 2016-08-26 |
| Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma (NCT02895360) | Basilea Pharmaceutica | 2016-08-24 |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors (NCT02897778) | Syndax Pharmaceuticals | 2016-08-24 |
| Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) (NCT02862457) | Merck Sharp & Dohme LLC | 2016-08-23 |
| Promoting Cancer Symptom Management in Older Adults (NCT03143829) | University of Central Florida | 2016-08-11 |
| The Circulating Cell-free Genome Atlas Study (NCT02889978) | GRAIL, Inc. | 2016-08-04 |
| A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors (NCT02825940) | Hoffmann-La Roche | 2016-08-04 |
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors (NCT02810418) | National Cancer Institute (NCI) | 2016-08-03 |
| Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma (NCT03422874) | Dartmouth-Hitchcock Medical Center | 2016-08-01 |